Comparison
While GHK-Cu acts as a tissue-remodeling and wound-healing signal, enhancing skin regeneration, angiogenesis, and repair while reducing inflammation and oxidative damage in experimental models31383, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While GHK-Cu works as an endogenous tripeptide, Gly-His-Lys, that chelates Cu²⁺ and modulates gene expression, stimulating collagen, elastin, proteoglycan, and glycosaminoglycan synthesis while exerting antioxidant and anti-inflammatory effects31383, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
GHK-Cu is 3 amino acids long, whereas PT-141 is longer as it has a length of 7 amino acids. GHK-Cu is made up of a sequence of Glycine, Histidine, Lysine. PT-141 is made up of a sequence of sequence data not available in the current dataset.
GHK-Cu
Not assigned in the current dataset.
PT-141
POMC